This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2007 by Introgen Therapeutics.
Recruitment status was:  Recruiting
Information provided by:
Introgen Therapeutics Identifier:
First received: July 11, 2002
Last updated: September 10, 2007
Last verified: September 2007
There is a need for more treatment options for patients with recurrent squamous cell cancer of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that include disruption of the p53 pathway, a pathway that would ordinarily work to prevent the development of tumors. In this study the transfer of the p53 gene to tumor cells using a modified adenovirus (INGN 201) in combination with chemotherapy (cisplatin and fluorouracil) will be compared to chemotherapy with cisplatin and fluorouracil in patients who have failed surgery and radiotherapy.

Condition Intervention Phase
Carcinoma, Squamous Cell Genetic: INGN 201 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Further study details as provided by Introgen Therapeutics:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • 18 years or older
  • Must have had radiation treatment
  • Eligible for chemotherapy
  • Not eligible for surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00041626

Contact: Introgen Therapeutics, Inc. 866.631.4646

United States, Arkansas
University of Arkansas Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Karen Duvall    501-526-7129   
Principal Investigator: James Suen, MD         
United States, Colorado
Unversity of Colorado Cancer Center Recruiting
Aurora, Colorado, United States, 80045
Contact: Brittney Hines    720-848-0678   
Principal Investigator: Madeleine Kane, MD         
United States, Florida
University of Miami Hospital and Sylvester Comprehensive Cancer Center Recruiting
Miami, Florida, United States, 33136
Contact: Andrea Gachupin-Garcia    305-243-3379   
Principal Investigator: Jarrad Goodwin, MD         
United States, Kentucky
Norton Healthcare Pavilion Recruiting
Louisville, Kentucky, United States, 40202
Contact: Daniela Neamtu    502-629-4679   
Principal Investigator: John Hamm, MD         
United States, Maryland
Center Center of GBMC Recruiting
Baltimore, Maryland, United States, 21204
Contact: Lauren Titus    443-849-3285   
Principal Investigator: Marshall Levine, MD         
United States, South Carolina
WJB Dorn VA Medical Center Recruiting
Columbia, South Carolina, United States, 29209
Contact: Justin Reynolds    803-776-4000 ext 6074   
Principal Investigator: William Hrushesky, MD         
United States, Texas
Mary Crowley Medical Research Center Recruiting
Dallas, Texas, United States, 75201
Contact: Arlen Waclawczyk    214-658-1985   
Principal Investigator: John Nemunaitis, MD         
University of Texas, MD Andersen Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Aida Berryman    713-745-1428   
Principal Investigator: Gary Clayman, MD         
Sponsors and Collaborators
Introgen Therapeutics
Study Director: Kerstin Menander, MD
Study Chair: Julie L Sicam, MT (ASCP) MSHS
  More Information Identifier: NCT00041626     History of Changes
Obsolete Identifiers: NCT00040716
Other Study ID Numbers: T302
Study First Received: July 11, 2002
Last Updated: September 10, 2007

Keywords provided by Introgen Therapeutics:
Recurrent Squamous Cell Carcinoma of the Head and Neck

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell processed this record on August 18, 2017